Genetic modulation of tumor antigen presentation.
An effective cancer-cell vaccine is created by expressing major-histocompatibility-complex (MHC) class II molecules without the invariant chain protein (Ii) that normally blocks the antigenic-peptide-binding site of MHC class II molecules at their synthesis in the endoplasmic reticulum. Such tumor-cell constructs are created either by the transfer of genes for MHC class IIalpha and beta chains, or by the induction of MHC class II molecules and Ii protein with a transacting factor, followed by Ii suppression using antisense methods. Preclinical validation of this approach is reviewed with the goal of using this immunotherapy for metastatic human cancers.
Xu
M
M
Antigen Express, One Innovation Drive, Worcester, MA 01605, USA.
Qiu
G
G
Jiang
Z
Z
von Hofe
E
E
Humphreys
R E
RE
D000818:Animals; D000944:Antigens, Differentiation, B-Lymphocyte / Q000235:genetics / Q000378:metabolism*; D000951:Antigens, Neoplasm / Q000235:genetics*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology / Q000378:metabolism; D019496:Cancer Vaccines / Q000235:genetics*; D004721:Endoplasmic Reticulum / Q000235:genetics / Q000378:metabolism; D000949:Histocompatibility Antigens Class II / Q000235:genetics* / Q000378:metabolism*; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D009362:Neoplasm Metastasis / Q000628:therapy; D014614:Vaccines, Synthetic / Q000235:genetics*
D000944:Antigens, Differentiation, B-Lymphocyte; D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D000949:Histocompatibility Antigens Class II; D014614:Vaccines, Synthetic; C045084:invariant chain